TECX Stock Forecast 2025-2026
Distance to TECX Price Targets
TECX Price Momentum
🤔 Considering Tectonic Therapeutic (TECX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest TECX Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, TECX has a bullish consensus with a median price target of $76.00 (ranging from $69.00 to $112.00). Currently trading at $25.63, the median forecast implies a 196.5% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tiago Fauth at Wells Fargo, projecting a 337.0% upside. Conversely, the most conservative target is provided by David Risinger at Leerink Partners, suggesting a 169.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TECX Analyst Ratings
TECX Price Target Range
Latest TECX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TECX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 31, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $112.00 |
| Nov 20, 2024 | Raymond James | Danielle Brill | Outperform | Initiates | $65.00 |
| Nov 12, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $79.00 |
| Nov 11, 2024 | Leerink Partners | David Risinger | Outperform | Maintains | $69.00 |
| Aug 22, 2024 | Wells Fargo | Tiago Fauth | Overweight | Initiates | $55.00 |
| Jul 24, 2024 | Leerink Partners | David Risinger | Outperform | Initiates | $49.00 |
| Jun 26, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Initiates | $76.00 |
| Jun 24, 2024 | TD Cowen | Tyler Van Buren | Buy | Initiates | $0.00 |
Tectonic Therapeutic Inc. (TECX) Competitors
The following stocks are similar to Tectonic Therapeutic based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tectonic Therapeutic Inc. (TECX) Financial Data
Tectonic Therapeutic Inc. has a market capitalization of $471.57M with a P/E ratio of -11.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -70.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Tectonic Therapeutic Inc. (TECX) Business Model
About Tectonic Therapeutic Inc.
Develops transformative therapies for complex diseases.
Tectonic Therapeutic Inc. operates a biopharmaceutical business model focused on discovering and developing innovative therapies that address unmet medical needs. The company generates revenue through collaborations with research institutions and industry partners, accelerating the development of its drug candidates and potentially earning returns from successful product commercialization.
Recognized for its influence in biotechnology and healthcare, Tectonic Therapeutic employs advanced technology platforms for precision medicine, aiming to improve patient outcomes. Its commitment to cutting-edge research positions the company as a significant player in the medical biotechnology sector, attracting attention from investors and stakeholders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
44
CEO
Dr. Alise S. Reicin M.D., Ph.D.
Country
United States
IPO Year
2018
Website
tectonictx.comTectonic Therapeutic Inc. (TECX) Latest News & Analysis
Tectonic Therapeutic, Inc. (NASDAQ: TECX) has secured a PIPE financing agreement expected to generate approximately $185 million in gross proceeds.
Tectonic Therapeutic's $185 million PIPE financing indicates strong investor confidence and provides significant capital for growth, impacting stock valuation and future projects.
TX45 shows positive interim results in a phase 1b study for pulmonary hypertension heart failure. Phase 1b results for reduced ejection fraction are due in H2 2025. Heart failure market projected at $33.7B by 2032.
Positive interim results for TX45 could indicate its potential as a valuable treatment, enhancing market position as the heart failure market grows to $33.7 billion by 2032.
Tectonic Therapeutic (NASDAQ: TECX) reported positive interim Phase 1b trial results for TX45, showing improved heart function and good tolerance in patients with PH-HFpEF, with no severe adverse events.
Positive interim data for TX45 suggests potential for significant advancements in treating PH-HFpEF, enhancing Tectonic's market position and potentially driving stock value higher.
Tectonic's TX45, an Fc-relaxin fusion protein for pulmonary hypertension, shows promise in early trials with favorable phase 1a results. Ongoing trials may position it as a market leader.
Tectonic's TX45 shows promise in treating a significant condition, with favorable trial results. Its potential as a market leader may drive acquisition interest, impacting stock value positively.
Tectonic Therapeutic, Inc. (NASDAQ: TECX) will host a virtual key opinion leader event on December 12, 2024, from 4 PM to 6 PM ET. Registration details are available.
Tectonic Therapeutic's KOL event could indicate upcoming insights on its pipeline, influencing investor sentiment and stock performance based on potential advancements in GPCR-targeting therapies.
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
3 months agoTectonic Therapeutic, Inc. (NASDAQ: TECX) will be presenting at the Piper Sandler 36th Annual Healthcare Conference in New York from December 3-5, 2024, by CEO Alise Reicin, MD.
Tectonic Therapeutic's presentation at a major healthcare conference highlights its progress in drug development, potentially influencing investor confidence and stock performance.
Frequently Asked Questions About TECX Stock
What is Tectonic Therapeutic Inc.'s (TECX) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Tectonic Therapeutic Inc. (TECX) has a median price target of $76.00. The highest price target is $112.00 and the lowest is $69.00.
Is TECX stock a good investment in 2025?
According to current analyst ratings, TECX has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $25.63. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TECX stock?
Wall Street analysts predict TECX stock could reach $76.00 in the next 12 months. This represents a 196.5% increase from the current price of $25.63. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tectonic Therapeutic Inc.'s business model?
Tectonic Therapeutic Inc. operates a biopharmaceutical business model focused on discovering and developing innovative therapies that address unmet medical needs. The company generates revenue through collaborations with research institutions and industry partners, accelerating the development of its drug candidates and potentially earning returns from successful product commercialization.
What is the highest forecasted price for TECX Tectonic Therapeutic Inc.?
The highest price target for TECX is $112.00 from Tiago Fauth at Wells Fargo, which represents a 337.0% increase from the current price of $25.63.
What is the lowest forecasted price for TECX Tectonic Therapeutic Inc.?
The lowest price target for TECX is $69.00 from David Risinger at Leerink Partners, which represents a 169.2% increase from the current price of $25.63.
What is the overall TECX consensus from analysts for Tectonic Therapeutic Inc.?
The overall analyst consensus for TECX is bullish. Out of 5 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $76.00.
How accurate are TECX stock price projections?
Stock price projections, including those for Tectonic Therapeutic Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
